Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

References

• Karno M, Goldin JM, Sorenson S B, et al. The epidemiology of obsessive compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094–9
   PubMed Web of Science ®Google Scholar
• Horwath E, Weissman MM. The epidemiology and cross-national presentation of obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:493–507
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD. Global Burden of Disease: a comprehensive assessment of mortality and morbidity from diseases, injuries and risk factors in 1990 and projected to 2020, Vol I. Harvard: World Health Organization, 1996
   Google Scholar
• Stein DJ, Allen A, Bobes J, et al. Quality of life in obsessive-compulsive disorder. CNS Spectr 2000;5 (S4):37–9
   Google Scholar
• Dupont RL, Rice DP, Shiraki S, et al. Economic costs of obsessive-compulsive disorder. Med Interface 1995;8:102–9
   PubMedGoogle Scholar
• Hollander E, Stein, DJ, Broatch J, et al. A pharmacoeconomic and quality of life study of obsessive-compulsive disorder. CNS Spectr 1997;2:16–25
   Google Scholar
• Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 2004;132:69–79
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005;162:228–38
   PubMed Web of Science ®Google Scholar
• Stein DJ. Seminar on obsessive-compulsive disorder. Lancet 2002;360:397–405
   PubMed Web of Science ®Google Scholar
• Stein DJ, Fineberg N, Seedat S. An integrated approach to the treatment of OCD. In: Fineberg, N, Marazziti, D, Stein DJ, eds. Obsessive-Compulsive Disorder: A Practical Guide. London: Martin Dunitz, 2001
   Google Scholar
• Ozaki N, Goldman D, Kaye WH, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003;8:933–6
   PubMed Web of Science ®Google Scholar
• Adams KH, Hansen ES, Pinborg LH, et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005;8:391–401
   PubMed Web of Science ®Google Scholar
• Thoren P, Åsberg M, Bertilsson L, et al. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980;37:1289–94
   PubMed Web of Science ®Google Scholar
• Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22 667–87
   PubMed Web of Science ®Google Scholar
• Joel D, Doljansky J, Roz N, et al. Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 2005;130:25–36
   PubMed Web of Science ®Google Scholar
• Eddy KT, Dutra L, Bradley R, et al. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011–30
   PubMed Web of Science ®Google Scholar
• Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309–17
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002;3:171–99
   PubMedGoogle Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567–96
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005;8:107–29
   PubMed Web of Science ®Google Scholar
• Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163–76
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17: 65–9
   Google Scholar
• Lader M, Stender K, Burger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomized, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241–8
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59: 22–33
   Google Scholar
• Goodman WK, Price LH, Rasmussen SA, et al. The Yale– Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006–11
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9
   PubMed Web of Science ®Google Scholar
• Insel TR, Murphy DL, Cohen R M, et al. National Institute of Mental Health Obsessive-Compulsive Scale (NIMH-OC). Arch Gen Psychiatry 1983;46:5–12
   Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76–338. 1976. Rockville, MD, National Institute of Mental Health
   Google Scholar
• Stewart SE, Geller DA, Jenike M, et al. Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psych Scand 2004;110:4–13
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive compulsive disorder. Int Clin Psychopharmacol 2001;16:75–86
   PubMed Web of Science ®Google Scholar
• Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int Clin Psychopharmacol 2002;5:181–91
   Google Scholar
• Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62 (S12):5–9
   PubMed Web of Science ®Google Scholar
• Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:509–17
   PubMed Web of Science ®Google Scholar
• Di Bella D, Erzegovesi S, Cavallini MC, et al. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J 2002;2:176–81
   PubMedGoogle Scholar
• Mataix-Cols D, Rauch SL, Manzo PA, et al. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999;156:1409–16
   Google Scholar